Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Malignant Melanoma

  Free Subscription

Articles published in Br J Cancer

Retrieve available abstracts of 38 articles:
HTML format

Single Articles

    March 2023
  1. RODRIGUES A, Cosman R, Joshua AM
    LXS196 for Metastatic Uveal Melanoma - finally some progress.
    Br J Cancer. 2023 Mar 1. doi: 10.1038/s41416-023-02199.

    January 2023
  2. PIPERNO-NEUMANN S, Carlino MS, Boni V, Loirat D, et al
    A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma.
    Br J Cancer. 2023 Jan 9. doi: 10.1038/s41416-022-02133.
    PubMed     Abstract available

    December 2022
  3. VAN DER KOOIJ MK, Joosse A, Suijkerbuijk KPM, Aarts MJB, et al
    Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study.
    Br J Cancer. 2022 Dec 23. doi: 10.1038/s41416-022-02088.

    November 2022
  4. EGGER S, Smith DP, Patel MI, Kimlin MG, et al
    Cutaneous melanoma, prostate-specific antigen testing and the subsequent risk of prostate cancer diagnosis: a prospective analysis of the 45 and Up Study.
    Br J Cancer. 2022 Nov 1. pii: 10.1038/s41416-022-02027.
    PubMed     Abstract available

    October 2022
  5. BUTLER EN, Zhou CK, Curry M, McMenamin U, et al
    Testosterone therapy and cancer risks among men in the SEER-Medicare linked database.
    Br J Cancer. 2022 Oct 28. pii: 10.1038/s41416-022-02019.
    PubMed     Abstract available

    August 2022
  6. JUNG S, Armstrong E, Wei AZ, Ye F, et al
    Clinical and genomic correlates of imatinib response in melanomas with KIT alterations.
    Br J Cancer. 2022 Aug 23. pii: 10.1038/s41416-022-01942.
    PubMed     Abstract available

    July 2022
  7. LI Y, Wang Q, Chen Y, Zhao L, et al
    Somatic mutations in DCC are associated with genomic instability and favourable outcomes in melanoma patients treated with immune checkpoint inhibitors.
    Br J Cancer. 2022 Jul 23. pii: 10.1038/s41416-022-01921.
    PubMed     Abstract available

    June 2022
  8. BARCELO C, Siso P, de la Rosa I, Megino-Luque C, et al
    M-CSF as a therapeutic target in BRAF(V600E) melanoma resistant to BRAF inhibitors.
    Br J Cancer. 2022 Jun 20. pii: 10.1038/s41416-022-01886.
    PubMed     Abstract available

  9. BREST P, Refae S, Mograbi B, Ferrero JM, et al
    Checkpoint inhibitors in a marriage: consented or arranged?
    Br J Cancer. 2022;126:1834-1836.
    PubMed     Abstract available

    April 2022
  10. LUNDBERG A, Li B, Li R
    B cell-related gene signature and cancer immunotherapy response.
    Br J Cancer. 2022;126:899-906.
    PubMed     Abstract available

    March 2022
  11. RAMTOHUL T, Cohen A, Rodrigues M, Piperno-Neumann S, et al
    Tumour growth rate improves tumour assessment and first-line systemic treatment decision-making for immunotherapy in patients with liver metastatic uveal melanoma.
    Br J Cancer. 2022 Mar 26. pii: 10.1038/s41416-022-01793.
    PubMed     Abstract available

  12. KUMAR PR, Saad M, Hellmich C, Mistry JJ, et al
    PGC-1alpha induced mitochondrial biogenesis in stromal cells underpins mitochondrial transfer to melanoma.
    Br J Cancer. 2022 Mar 26. pii: 10.1038/s41416-022-01783.
    PubMed     Abstract available

  13. WOOF VG, Lee RJ, Lorigan P, French DP, et al
    Circulating tumour DNA monitoring and early treatment for relapse: views from patients with early-stage melanoma.
    Br J Cancer. 2022 Mar 17. pii: 10.1038/s41416-022-01766.
    PubMed     Abstract available

  14. VAN BREESCHOTEN J, Wouters MWJM, Hilarius DL, Haanen JB, et al
    Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients: a propensity-matched survival analysis.
    Br J Cancer. 2022 Mar 7. pii: 10.1038/s41416-022-01772.

    February 2022
  15. BEASLEY AB, Chen FK, Isaacs TW, Gray ES, et al
    Future perspectives of uveal melanoma blood based biomarkers.
    Br J Cancer. 2022 Feb 21. pii: 10.1038/s41416-022-01723.
    PubMed     Abstract available

    November 2021
  16. HAMIS SJ, Kapelyukh Y, McLaren A, Henderson CJ, et al
    Quantifying ERK activity in response to inhibition of the BRAFV600E-MEK-ERK cascade using mathematical modelling.
    Br J Cancer. 2021;125:1552-1560.
    PubMed     Abstract available

    October 2021
    Checkpoint blocker induced autoimmunity as an indicator for tumour efficacy in melanoma.
    Br J Cancer. 2021 Oct 25. pii: 10.1038/s41416-021-01390.
    PubMed     Abstract available

    August 2021
  18. MARSAVELA G, McEvoy AC, Pereira MR, Reid AL, et al
    Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression.
    Br J Cancer. 2021 Aug 9. pii: 10.1038/s41416-021-01507.
    PubMed     Abstract available

    July 2021
  19. BOUCHEREAU S, Chaplain L, Fort M, Beauchet A, et al
    Impact of prior treatment with immune checkpoint inhibitors on dacarbazine efficacy in metastatic melanoma.
    Br J Cancer. 2021 Jul 14. pii: 10.1038/s41416-021-01486.
    PubMed     Abstract available

    June 2021
  20. MAIQUES O, Fanshawe B, Crosas-Molist E, Rodriguez-Hernandez I, et al
    A preclinical pipeline to evaluate migrastatics as therapeutic agents in metastatic melanoma.
    Br J Cancer. 2021 Jun 25. pii: 10.1038/s41416-021-01442.
    PubMed     Abstract available

    May 2021
  21. WEBER A, Leitzmann MF, Sedlmeier AM, Baurecht H, et al
    Association between physical activity, grip strength and sedentary behaviour with incidence of malignant melanoma: results from the UK Biobank.
    Br J Cancer. 2021 May 31. pii: 10.1038/s41416-021-01443.
    PubMed     Abstract available

    April 2021
  22. DHOMEN N, Mundra PA, Marais R
    Sunglasses to hide behind may also prevent melanoma of the eyes.
    Br J Cancer. 2021 Apr 6. pii: 10.1038/s41416-021-01343.
    PubMed     Abstract available

  23. WANG H, Elsheikh M, Gilmour K, Cohen V, et al
    Impact of COVID-19 pandemic on eye cancer care in United Kingdom.
    Br J Cancer. 2021;124:1357-1360.
    PubMed     Abstract available

    March 2021
  24. VAN BREESCHOTEN J, Wouters MWJM, Hilarius DL, Haanen JB, et al
    Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients: a propensity-matched survival analysis.
    Br J Cancer. 2021 Mar 15. pii: 10.1038/s41416-021-01312.

  25. YE W, Olsson-Brown A, Watson RA, Cheung VTF, et al
    Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles.
    Br J Cancer. 2021 Mar 15. pii: 10.1038/s41416-021-01310.
    PubMed     Abstract available

  26. YAO S, Janku F, Subbiah V, Stewart J, et al
    Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies.
    Br J Cancer. 2021 Mar 5. pii: 10.1038/s41416-020-01230.
    PubMed     Abstract available

  27. KATO R, Haratani K, Hayashi H, Sakai K, et al
    Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts.
    Br J Cancer. 2021;124:914-924.
    PubMed     Abstract available

    February 2021
  28. BARCLAY ME, Abel GA, Greenberg DC, Rous B, et al
    Socio-demographic variation in stage at diagnosis of breast, bladder, colon, endometrial, lung, melanoma, prostate, rectal, renal and ovarian cancer in England and its population impact.
    Br J Cancer. 2021 Feb 9. pii: 10.1038/s41416-021-01279.
    PubMed     Abstract available

    January 2021
  29. VAN BREESCHOTEN J, Wouters MWJM, Hilarius DL, Haanen JB, et al
    First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients: a propensity-matched survival analysis.
    Br J Cancer. 2021 Jan 26. pii: 10.1038/s41416-020-01229.
    PubMed     Abstract available

    December 2020
  30. AMERATUNGA M, Brana I, Bono P, Postel-Vinay S, et al
    First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours.
    Br J Cancer. 2020;123:1730-1736.
    PubMed     Abstract available

    November 2020
  31. KUMAR PR, Moore JA, Bowles KM, Rushworth SA, et al
    Mitochondrial oxidative phosphorylation in cutaneous melanoma.
    Br J Cancer. 2020 Nov 18. pii: 10.1038/s41416-020-01159.
    PubMed     Abstract available

  32. SMITH AJ, Lambert PC, Rutherford MJ
    Understanding the impact of sex and stage differences on melanoma cancer patient survival: a SEER-based study.
    Br J Cancer. 2020 Nov 4. pii: 10.1038/s41416-020-01144.
    PubMed     Abstract available

    October 2020
  33. BHAVE P, Pallan L, Long GV, Menzies AM, et al
    Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis.
    Br J Cancer. 2020 Oct 22. pii: 10.1038/s41416-020-01121.
    PubMed     Abstract available

  34. PAMIDIMUKKALA N, Puts GS, Kathryn Leonard M, Snyder D, et al
    Nme1 and Nme2 genes exert metastasis-suppressor activities in a genetically engineered mouse model of UV-induced melanoma.
    Br J Cancer. 2020 Oct 7. pii: 10.1038/s41416-020-01096.
    PubMed     Abstract available

  35. RABBIE R, Ferguson P, Wong K, Couturier DL, et al
    The mutational landscape of melanoma brain metastases presenting as the first visceral site of recurrence.
    Br J Cancer. 2020 Oct 7. pii: 10.1038/s41416-020-01090.
    PubMed     Abstract available

    August 2020
  36. ALMEIDA RR, Vieira RS, Castoldi A, Terra FF, et al
    Host dysbiosis negatively impacts IL-9-producing T-cell differentiation and antitumour immunity.
    Br J Cancer. 2020;123:534-541.
    PubMed     Abstract available

    July 2020
  37. CHEUNG VTF, Gupta T, Olsson-Brown A, Subramanian S, et al
    Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?
    Br J Cancer. 2020;123:207-215.
    PubMed     Abstract available

    April 2020
  38. MCNEILLIS R, Greystoke A, Walton J, Bacon C, et al
    A case of malignant hyperlactaemic acidosis appearing upon treatment with the mono-carboxylase transporter 1 inhibitor AZD3965.
    Br J Cancer. 2020;122:1141-1145.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.